<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04807010</url>
  </required_header>
  <id_info>
    <org_study_id>001</org_study_id>
    <nct_id>NCT04807010</nct_id>
  </id_info>
  <brief_title>PROARTE -PROstate ARTery to Reduce the Symptoms of Benign Prostatic Hyperplasia</brief_title>
  <acronym>PROARTE</acronym>
  <official_title>PROARTE -PROstate ARTery to Reduce the Symptoms of Benign Prostatic Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Society of Interventional Radiology Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Society of Interventional Radiology Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a trial to demonstrate the superiority of prostate artery embolization (PAE) over&#xD;
      sham procedure in men with benign prostatic hyperplasia (BPH) induced lower urinary tract&#xD;
      symptoms (LUTS). The trial will aim to enroll 108 patients at a 2:1 allocation over a 2 year&#xD;
      period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Patients and those recording response will be blinded to cohort allocation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>International Prostate Symptom Score</measure>
    <time_frame>6 months</time_frame>
    <description>A survey accessing patient symptomology from BPH induced LUTS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>International Prostate Symptom Score</measure>
    <time_frame>1, 3, 6, 9, 12, 24, 36 months</time_frame>
    <description>A survey accessing patient symptomology from BPH induced LUTS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>1, 3, 6, 9, 12, 24, 36 months</time_frame>
    <description>A survey accessing quality of life impact on patients from BPH induced LUTS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal urinary flow rate change from baseline</measure>
    <time_frame>6, 12, 24, and 36 months</time_frame>
    <description>Maximal flow rate of urine stream</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post void residual change from baseline</measure>
    <time_frame>6, 12, 24, and 36 months</time_frame>
    <description>Post void residual measures the volume of urine remaining in the bladder after complete emptying.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Index of Erectile Function questionnaire (IIEF)</measure>
    <time_frame>1, 3, 6, 9, 12, 24, 36 months</time_frame>
    <description>A questionnaire designed to asses erectile function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from secondary intervention to treat BPH</measure>
    <time_frame>1, 3, 6, 9, 12, 24, 36 months</time_frame>
    <description>Recording of other surgical/procedural treatments with each procedure being recorded as an event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ejaculatory function</measure>
    <time_frame>3, 6, 9, 12, 24, 36 months</time_frame>
    <description>Ejaculatory function will be assessed utilizing a four item questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Continence</measure>
    <time_frame>1, 6, and 12 months</time_frame>
    <description>Urinary Continence will be assessed using a 2 item questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospital days</measure>
    <time_frame>1 month</time_frame>
    <description>Number of hospital days following the procedure will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recover experience</measure>
    <time_frame>1 month</time_frame>
    <description>Recover experience will be assessed using a quality of recovery visual analog scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>7 days and 1, 3, 6, 9, 12, 24, 36 months</time_frame>
    <description>All procedure related adverse events will be recoreded</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <condition>Lower Urinary Tract Symptoms</condition>
  <arm_group>
    <arm_group_label>Prostate artery embolization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Prostate Artery Embolization</intervention_name>
    <description>Prostate artery embolization reduces symptoms from benign prostatic hyperplasia by delivering embolic materials to the prostate through the prostatic arteries.</description>
    <arm_group_label>Prostate artery embolization</arm_group_label>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham Prostate Artery Embolization</intervention_name>
    <description>Angiogram without embolization initially. At 6 months patients will be allowed to crossover to prostate artery embolization.</description>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Men ≥45 and ≤90 years presenting with benign prostatic hyperplasia with symptoms for&#xD;
             at least 6 months that are refractory to medical management or in whom medications are&#xD;
             contraindicated, not tolerated, or refused.&#xD;
&#xD;
               -  International Prostate Symptom Score (I-PSS) score 14 or greater.&#xD;
&#xD;
               -  Quality of Life (QoL) score ≥ 3&#xD;
&#xD;
               -  Peak urinary flow (Qmax) less than or equal to 12 mL/s with void volume &gt;125mL.&#xD;
&#xD;
               -  Prostate volume greater than 30 cc as determined by ultrasound, MRI, or CT.&#xD;
&#xD;
               -  Personal risk &lt;40% based on the University of Texas San Antonio prostate cancer&#xD;
                  risk calculator or having a negative prostate biopsy for cancer within the last&#xD;
                  24 months.&#xD;
&#xD;
               -  Able to provide written consent.&#xD;
&#xD;
               -  Not participating in any other investigational drug or device studies.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • History of biopsy-proven prostate cancer&#xD;
&#xD;
               -  Renal insufficiency (glomerular filtration rates (GFR) less than 40mL/min/1.73 m2&#xD;
                  who are not already on dialysis)&#xD;
&#xD;
               -  Prior prostate surgery or intervention, including trans-urethral resection of the&#xD;
                  prostate, balloon dilation, stent implantation, laser prostatectomy, radiation,&#xD;
                  UroLift®, or hyperthermia&#xD;
&#xD;
               -  Other bladder or urethral pathology requiring therapy, either in the past or&#xD;
                  currently, including neurogenic bladder, sphincteric abnormalities, bladder&#xD;
                  cancer, or other causes of bladder atonia.&#xD;
&#xD;
               -  Other causes of urinary obstruction, such as strictures of urethra or ureters,&#xD;
                  not related to BPH&#xD;
&#xD;
               -  Current decompensated congestive heart failure, uncontrolled diabetes mellitus,&#xD;
                  significant respiratory disease, or known immunosuppression.&#xD;
&#xD;
               -  Neurological disease, including multiple sclerosis, amyotrophic lateral&#xD;
                  sclerosis, Parkinson's disease, and previous spinal nerve surgery&#xD;
&#xD;
               -  Patients with platelet count &lt;50,000/μL or International Normalized Ratio (INR)&#xD;
                  &gt;1.8, unless corrected for the procedure&#xD;
&#xD;
               -  Active urinary tract infection. Patients must have a negative culture within 7&#xD;
                  days of the procedure.&#xD;
&#xD;
               -  Allergy to iodinated contrast agents unless pre-treated by corticosteroids.&#xD;
&#xD;
               -  Acute urinary retention.&#xD;
&#xD;
               -  Post void residual (PVR) &gt; 250 mL with urodynamic evidence of atonic bladder.&#xD;
                  Patients with a PVR &gt;250 but urodynamic testing consistent with obstruction will&#xD;
                  be allowed.&#xD;
&#xD;
               -  Bladder stone within three months prior to the procedure.&#xD;
&#xD;
               -  Hematuria not evaluated by Urologist for causes other than BPH.&#xD;
&#xD;
               -  Previous rectal surgery (excluding hemorrhoidectomy) or history of rectal&#xD;
                  disease.&#xD;
&#xD;
               -  Prior pelvic irradiation or radical pelvic surgery.&#xD;
&#xD;
        Imaging exclusion criteria:&#xD;
&#xD;
        • Internal iliac artery occlusion as determined by either CT or MRI.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Patients must be male, as they are the only ones who suffer from BPH induced LUTS</gender_description>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shamar Young, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jafar Golzarian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pooja Doshi</last_name>
    <phone>703-460-5580</phone>
    <phone_ext>580</phone_ext>
    <email>pdoshi@sirweb.org</email>
  </overall_contact>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>March 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2021</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate artery embolization</keyword>
  <keyword>Benign Prostatic Hyperplasia</keyword>
  <keyword>Lower Urinary Tract Symptoms</keyword>
  <keyword>Quality of Life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

